MFW
HZNP

Meristem Family Wealth’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Meristem Family Wealth’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$332K Hold
3,154
– – 0.04% 248
2021
Q4 		$340K Hold
3,154
– – 0.03% 282
2021
Q3 		$345K Buy
3,154
+254
+9% +$26.4K 0.03% 285
2021
Q2 		$272K Buy
+2,900
New +$267K 0.04% 270

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Meristem Family Wealth's HZNP Position: Q1 2022 in Review

Meristem Family Wealth held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q1 2022 at 3,154 shares worth $332K. The position accounts for 0.04% of the portfolio, ranked #248.

Meristem Family Wealth first reported a position in HZNP in Q2 2021 and has held it in 4 quarters since. The position peaked at $345K in Q3 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

  • Meristem Family Wealth held 3,154 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $332K as of Q1 2022.
  • Meristem Family Wealth left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q1 2022.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.04% of Meristem Family Wealth's portfolio in Q1 2022, its #248 holding.
  • Meristem Family Wealth first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and has held it in 4 quarters since.
  • Meristem Family Wealth's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $345K in Q3 2021.
  • 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Meristem Family Wealth's 13F filing for Q1 2022, filed 11 May 2022.